New study reveals CADUET two-in-one pill dramatically improves patient adherence



    -Patient adherence essential in reducing risk of cardiovascular disease-

    KIRKLAND, QC, July 7 /CNW/ - Despite the proven benefits of blood
pressure and cholesterol medications for the prevention of cardiovascular
events(1) and guidelines supporting an integrated approach to the reduction of
cardiovascular risk,(2) few patients receive adequate treatment for the
prevention of cardiovascular disease. This is due in part to poor patient
adherence to cardiovascular medications.
    According to a new study, Adherence with single-pill
amlodipine/atorvastatin versus a two-pill regimen, published in this month's
Vascular Health and Risk Management, patients taking CADUET(R) were more
likely to be adherent and persistent with therapy compared to patients taking
calcium channel blockers (CCB) and statins as two separate pills. CADUET
combines the efficacy of the blood pressure lowering medication, NORVASC(R),
with the cholesterol and cardiovascular risk reduction of LIPITOR(R).
    "The findings from this study reinforce the importance of adherence when
it comes to managing a person's risk factors for cardiovascular disease," says
Dr. George Honos, Associate Professor of Medicine, McGill University,
Montreal. "CADUET allows me to simplify my patients' treatment regime by
providing them with the proven benefits of two leading treatments in the
convenience of one single pill. By reducing pill burden and synchronizing high
blood pressure and high cholesterol treatment, we are significantly helping to
reduce our patient's chance of suffering a heart attack or stroke."

    Managing Multiple Risk Factors Early

    Cardiovascular disease, including heart disease and stroke, is the
leading cause of death in Canada.(3) Unfortunately, Canadians run a high risk
of developing cardiovascular disease. Research shows that an alarming 80 per
cent of Canadians have at least one modifiable risk factor for cardiovascular
disease, such as high cholesterol, hypertension, obesity and a sedentary
lifestyle.(4)
    A number of studies, including the Anglo-Scandinavian Cardiac Outcomes
Trial (ASCOT), have shown that managing multiple risk factors may help to
significantly reduce a patient's likelihood of suffering a cardiovascular
event. The ASCOT study found that using a NORVASC-based blood pressure
lowering treatment regimen in combination with LIPITOR, a statin,
significantly reduced cardiovascular events, such as heart attacks, in
patients with high blood pressure and additional cardiovascular risk factors.

    About CADUET

    CADUET is a prescription drug that combines two medicines, NORVASC
(amlodipine besylate) and LIPITOR (atorvastatin calcium), which have been
extensively studied in clinical trials.

    NORVASC is a prescription drug indicated in the treatment of mild to
moderate essential hypertension. NORVASC is also indicated for the management
of chronic stable angina (effort-associated angina) in patients who remain
symptomatic despite adequate dose of beta blockers and/or organic nitrates or
who cannot tolerate those agents.

    LIPITOR is a drug prescribed to lower cholesterol and other fats in the
blood (such as triglycerides) when response to diet and other lifestyle
measures have been inadequate, in both adults and children (aged 10 to 17
years). LIPITOR is also indicated to prevent cardiovascular disease such as
heart attacks. High levels of cholesterol and other fats can cause heart
disease by clogging the blood vessels that feed blood and oxygen to the heart.
    The two agents forming CADUET are still available separately.

    About Pfizer Canada Inc.

    Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., the world's
leading pharmaceutical company. Pfizer discovers, develops, manufactures and
markets prescription medicines for humans and animals. Pfizer's ongoing
research and development activities focus on a wide range of therapeutic areas
following our guiding aspiration: working together for a healthier world. For
more information, visit www.pfizer.ca.

    REFERENCES:

    (1) ALLHAT Officers and Coordinator for the ALLHAT Collaborative Research
    Group, 2002; Sever, et al 2003; Staessen et al 2003; Baigent et al 2005.
    (2) Expert Panel on Detection Evaluation and Treatment of High
    Cholesterol in Adults, 2001).
    (3) http://www.hc-sc.gc.ca/dc-ma/heart-coeur/index-eng.php
    (4) Tipping the Scales of Progress. Heart Disease and Stroke in Canada,
    2006. Heart and Stroke Foundation of Canada.
    http://ww2.heartandstroke.ca/images/english/Tipping_the_Scales.pdf





For further information:

For further information: Laura Espinoza, Edelman, (416) 979-1120, ext.
245, laura.espinoza@edelman.com; Christian Marcoux, Pfizer Canada Inc., (514)
426-6985, christian.marcoux@pfizer.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890